Skip to main content
Livermore
Livermore
ZHEN

Foresite Capital Management VI LLC

SEC CIK
0002013341
Latest filing
Aug 14, 2026

The latest 13F from Foresite Capital Management VI LLC covers Q2 2026 (filed Aug 14, 2026): 23 long positions worth $642.6M. The top 10 holdings make up 81.5% of the portfolio, and the largest is CG Oncology, Inc. (CGON) at 26.2%. Livermore has 7 filings on Form 13F from this institution, going back to Q4 2024.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
8
Est. +$101.4M
Added
6
Est. +$75.3M
Reduced
1
Est. −$5.64K
Sold out
2
Est. −$60.2M

Top 5 holdings

Share of this quarter's portfolio value

  1. CGONCG Oncology, Inc.
    26.2%$168.4MHistory
  2. ALMSAlumis Inc.
    18.6%$119.5MHistory
  3. SPTXSeaport Therapeutics, Inc.
    6.0%$38.7MHistory
  4. DNLIDenali Therapeutics Inc.
    5.6%$35.9MHistory
  5. CLDXCelldex Therapeutics, Inc.
    5.1%$32.7MHistory

Share of portfolio

Top 5 holdings and the other 18 positions, by share of portfolio value

  1. CGON26.2%
  2. ALMS18.6%
  3. SPTX6.0%
  4. DNLI5.6%
  5. CLDX5.1%
  6. Other 18 positions38.5%

Biggest buys

New and added positions, by estimated amount bought

  1. SPTXSeaport Therapeutics, Inc.
    +$38.7MNewHistory
  2. PBLSParabilis Medicines, Inc.
    +$27.3MNewHistory
  3. CLDXCelldex Therapeutics, Inc.
    +$21.0MAddedHistory
  4. GHRSGH Research PLC
    +$16.8MAddedHistory
  5. JBIOJade Biosciences, Inc.
    +$12.6MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. SPTXSeaport Therapeutics, Inc.
    +6.02 pp0.0% → 6.0%History
  2. PBLSParabilis Medicines, Inc.
    +4.26 pp0.0% → 4.3%History
  3. GHRSGH Research PLC
    +2.97 pp1.0% → 3.9%History
  4. CLDXCelldex Therapeutics, Inc.
    +2.92 pp2.2% → 5.1%History
  5. JBIOJade Biosciences, Inc.
    +2.09 pp1.0% → 3.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CNTACentessa Pharmaceuticals plc
    −$54.2MSold outHistory
  2. OKUROnKure Therapeutics, Inc.
    −$5.99MSold outHistory
  3. NERVMinerva Neurosciences, Inc.
    −$5.64KReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CNTACentessa Pharmaceuticals plc
    −11.77 pp11.8% → 0.0%History
  2. OKUROnKure Therapeutics, Inc.
    −1.30 pp1.3% → 0.0%History
  3. NERVMinerva Neurosciences, Inc.
    −0.89 pp2.6% → 1.7%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$642.6M
+$182.3M (+39.6%) vs. prior quarter
Positions
23
+6 vs. prior quarter
Top 10 concentration
81.5%
Top 10 as share of value
Turnover
10.9%
Q2 2026, one quarter
Average holding period
4.7 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2024), so positions held before then are understated.

13F filings by quarter

7 quarters, going back to Q4 2024. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $642.6M (Q2 2026)

Q4 2024: $224.4MQ1 2025: $182.5MQ2 2025: $177.9MQ3 2025: $258.9MQ4 2025: $330.8MQ1 2026: $460.3MQ2 2026: $642.6M
Q4 2024Q2 2026
13F filings of Foresite Capital Management VI LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202623$642.6MCGONALMSSPTXvs. Q1 2026SEC
Q1 2026May 15, 202617$460.3MCGONALMSCNTAvs. Q4 2025SEC
Q4 2025Feb 17, 202612$330.8MCGONRAPTALMSvs. Q3 2025SEC
Q3 2025Nov 14, 202512$258.9MCGONRAPTCNTAvs. Q2 2025SEC
Q2 2025Aug 12, 202520$177.9MCGONCNTAAKROvs. Q1 2025SEC
Q1 2025May 15, 202514$182.5MCGONALMSCNTAvs. Q4 2024SEC
Q4 2024Feb 14, 202514$224.4MCGONALMSCNTA–SEC

13D and 13G filings

Companies where Foresite Capital Management VI LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Foresite Capital Management VI LLC does not currently report owning 5% or more of any company.

Latest filings

14 filings on file made by Foresite Capital Management VI LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Foresite Capital Management VI LLC
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
LTGOLatigo Biotherapeutics, Inc.Aug 17, 20267:06 PM ETForesite Capital Fund VI LPand 6 others13D14.50%9.18M sharesNewAug 10, 2026SEC
ALMSAlumis Inc.Aug 17, 20266:09 AM ETForesite Capital Fund VI LPand 6 others13D14.50%9.18M sharesNewAug 10, 2026SEC
CGONCG Oncology, Inc.Aug 14, 20264:01 PM ETForesite Capital Fund V, L.P.and 6 others13G/A4.90%4.31M shares–Below 5%Jun 30, 2026SEC
VSTMVerastem, Inc.May 15, 20264:21 PM ETForesite Capital Fund VI LPand 2 others13G/A3.60%3.15M shares−1.50 ppfrom 5.10%Below 5%Mar 31, 2026SEC
ALMSAlumis Inc.Apr 3, 20263:51 PM ETForesite Capital Fund VI LPand 11 others13D/A12.70%15.7M shares−1.40 ppfrom 14.10%Apr 1, 2026SEC
CASIFCASI Pharmaceuticals, Inc.Feb 13, 20266:03 PM ETForesite Capital Fund VI LPand 2 others13G/A0.00%0 shares−6.30 ppfrom 6.30%Below 5%Dec 31, 2025SEC
ALMSAlumis Inc.Jan 12, 20269:59 PM ETForesite Capital Fund VI LPand 11 others13D/A14.10%16.2M shares−1.80 ppfrom 15.90%Jan 8, 2026SEC
CASIFCASI Pharmaceuticals, Inc.Nov 14, 20254:05 PM ETForesite Capital Fund VI LPand 2 others13G/A6.30%980.0K shares+1.20 ppfrom 5.10%Sep 30, 2025SEC
VSTMVerastem, Inc.Oct 23, 20257:09 PM ETForesite Capital Fund VI LPand 2 others13G5.10%3.14M sharesNewOct 16, 2025SEC
CASIFCASI Pharmaceuticals, Inc.Aug 12, 20254:05 PM ETForesite Capital Fund VI LPand 2 others13G/A5.10%787.1K shares–Jun 30, 2025SEC
ALMSAlumis Inc.Jun 10, 20254:37 PM ETForesite Capital Fund VI LPand 11 others13D/A15.90%15.2M shares−16.30 ppfrom 32.20%May 21, 2025SEC
ALMSAlumis Inc.May 7, 20253:33 PM ETForesite Capital Fund VI LPand 11 others13D/A32.20%15.2M shares–Aug 13, 2024SEC
ENGNenGene Therapeutics Inc.Feb 14, 20252:25 PM ETForesite Capital Fund VI LPand 2 others13G/A0.00%0 shares–Below 5%Sep 30, 2024SEC
RAPTRAPT Therapeutics, Inc.Dec 30, 20243:32 PM ETForesite Capital Fund VI LPand 2 others13G9.30%12.5M sharesNewDec 23, 2024SEC